556 related articles for article (PubMed ID: 24172896)
1. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA
Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896
[TBL] [Abstract][Full Text] [Related]
2. Early antibody therapy can induce long-lasting immunity to SHIV.
Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
[TBL] [Abstract][Full Text] [Related]
3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.
Barouch DH; Whitney JB; Moldt B; Klein F; Oliveira TY; Liu J; Stephenson KE; Chang HW; Shekhar K; Gupta S; Nkolola JP; Seaman MS; Smith KM; Borducchi EN; Cabral C; Smith JY; Blackmore S; Sanisetty S; Perry JR; Beck M; Lewis MG; Rinaldi W; Chakraborty AK; Poignard P; Nussenzweig MC; Burton DR
Nature; 2013 Nov; 503(7475):224-8. PubMed ID: 24172905
[TBL] [Abstract][Full Text] [Related]
5. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
7. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
[TBL] [Abstract][Full Text] [Related]
8. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
9. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
10. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.
Ho SH; Shek L; Gettie A; Blanchard J; Cheng-Mayer C
J Virol; 2005 Oct; 79(19):12296-303. PubMed ID: 16160156
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
12. Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.
Ren W; Mumbauer A; Zhuang K; Harbison C; Knight H; Westmoreland S; Gettie A; Blanchard J; Cheng-Mayer C
Retrovirology; 2013 Jan; 10():9. PubMed ID: 23369442
[TBL] [Abstract][Full Text] [Related]
13. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
[TBL] [Abstract][Full Text] [Related]
14. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
Laird ME; Igarashi T; Martin MA; Desrosiers RC
J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
[TBL] [Abstract][Full Text] [Related]
15. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
16. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
17. HIV: advancing the antibody approach.
Bird L
Nat Rev Immunol; 2013 Dec; 13(12):846-7. PubMed ID: 24409525
[No Abstract] [Full Text] [Related]
18. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
19. HIV: Antibodies advance the search for a cure.
Picker LJ; Deeks SG
Nature; 2013 Nov; 503(7475):207-8. PubMed ID: 24172894
[No Abstract] [Full Text] [Related]
20. Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.
Zhuang K; Finzi A; Toma J; Frantzell A; Huang W; Sodroski J; Cheng-Mayer C
Retrovirology; 2012 Dec; 9():106. PubMed ID: 23237529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
